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A neomorphic cancer cell-specific role
of MAGE-A4 in trans-lesion synthesis
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Trans-lesion synthesis (TLS) is an important DNA-damage tolerance mechanism that permits
ongoing DNA synthesis in cells harbouring damaged genomes. The E3 ubiquitin ligase RAD18
activates TLS by promoting recruitment of Y-family DNA polymerases to sites of
DNA-damage-induced replication fork stalling. Here we identify the cancer/testes antigen
melanoma antigen-A4 (MAGE-A4) as a tumour cell-specific RAD18-binding partner and an
activator of TLS. MAGE-A4 depletion from MAGE-A4-expressing cancer cells destabilizes
RAD18. Conversely, ectopic expression of MAGE-A4 (in cell lines lacking endogenous
MAGE-A4) promotes RAD18 stability. DNA-damage-induced mono-ubiquitination of the
RAD18 substrate PCNA is attenuated by MAGE-A4 silencing. MAGE-A4-depleted cells fail to
resume DNA synthesis normally following ultraviolet irradiation and accumulate gH2AX,
thereby recapitulating major hallmarks of TLS deficiency. Taken together, these results
demonstrate a mechanism by which reprogramming of ubiquitin signalling in cancer cells can
influence DNA damage tolerance and probably contribute to an altered genomic landscape.
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E
ukaryotic cells are exposed to many intrinsic and exogenous
sources of DNA damage. The S-phase of the cell cycle is
particularly vulnerable to genotoxins, because error-prone
replication of damaged DNA can lead to mutagenesis, a ‘hallmark
and enabling characteristic’ of cancer1. To mitigate the genome-
destabilizing consequences of DNA damage in S-phase, DNA
replication forks that encounter lesions trigger a network of signal
transduction pathways collectively termed the DNA damage
response (DDR). The different effector arms of the DDR
cooperate to facilitate S-phase recovery and resumption of
normal cell cycle progression following genotoxic insult2.
Failure to integrate DNA replication with DNA repair and cell
cycle progression leads to reduced viability, compromised
genome stability and a predisposition to cancer.
Trans-lesion synthesis (TLS) is one of the main effector
pathways of the DDR and is important for normal recovery from
DNA replication fork stalling3. The conventional DNA
polymerases that duplicate most of the genome every cell cycle
cannot replicate DNA templates harbouring bulky lesions.
Therefore, following acquisition of DNA damage, a ‘polymerase
switch’ replaces replicative DNA polymerases at stalled
replication forks with specialized TLS DNA polymerases that
can accommodate bulky lesions.
The Y-family TLS polymerases include DNA polymerase eta
(PolZ), DNA polymerase kappa (Polk), DNA polymerase iota
(Poli) and REV1 (refs 3,4). Collectively, Y-family TLS
polymerases enable cells to maintain DNA synthesis using
damaged genomes. In TLS-deficient cells, checkpoint kinase
signalling persists, leading to a protracted S-phase arrest and
accumulation of DNA double-stranded breaks (DSBs)5–7.
TLS can be error-free or error-prone depending on the nature
of the DNA damage and the particular TLS polymerase(s)
selected for lesion bypass3,4. PolZ is the default TLS polymerase
recruited to stalled replication forks and performs error-free
replication of DNA templates containing its cognate lesions
(including ultraviolet-induced cyclo-butane pyrimidine dimers),
thereby suppressing mutagenesis. However, when PolZ is absent,
error-prone compensatory lesion bypass by other Y-family DNA
polymerases leads to mutations8, a mechanism that explains the
ultraviolet sensitivity and skin cancer propensity of PolZ-deficient
xeroderma pigmentosum-Variant patients9. TLS must be
regulated strictly and used sparingly to ensure genomic stability.
Mono-ubiquitination of the DNA polymerase processivity
factor proliferating cell nuclear antigen (PCNA) is important for
TLS activation and lesion bypass10,11. In response to DNA
damage, the E3 ubiquitin ligase RAD18 is recruited to stalled
replication forks where it mono-ubiquitinates PCNA at the
conserved residue K164 (refs 12,13). K164 mono-ubiquitination
promotes interactions between PCNA and Y-family TLS
polymerases (which possess ubiquitin-binding zinc fingers and
ubiquitin-binding motifs) at stalled replication forks14.
RAD18 overexpression can increase PCNA mono-ubiquitina-
tion and promote recruitment of TLS polymerases to replication
forks, even in the absence of DNA damage5. Conversely, in
RAD18-deficient cells, Y-family TLS polymerases are not
recruited efficiently to sites of DNA replication stalling5,15,16
and overall lesion bypass is reduced17. Moreover, RAD18
deficiency recapitulates the defective S-phase recovery
phenotypes of PolZ and Polk-deficient cells after genotoxin
exposure5, supporting a major role for RAD18 in TLS.
Although RAD18 is important for TLS polymerase recruitment
to stalled replication forks, the basis for lesion-specific selection of
the correct TLS polymerase is not yet fully understood. All TLS
polymerases preferentially associate with mono-ubiquitinated
PCNA relative to unmodified species. Clearly, relative expression
levels and activities of RAD18 and the Y-family DNA
polymerases are likely to have an impact on the overall TLS
capacity and accuracy, determining mutagenic outcomes. Recent
sequencing efforts have demonstrated that cancer cell genomes
contain tens to hundreds of thousands of nucleotide substitutions
and other mutations18. Mutation rates of untransformed cells are
insufficient to explain the large numbers of mutations found in
cancer cells. Therefore, cancer may be associated with a ‘mutator
phenotype’ that generates large numbers of driver and passenger
mutations during tumour progression19,20. Owing to its pivotal
role in error-prone DNA synthesis, RAD18-mediated TLS has the
potential to contribute to the mutational burden of cancer
genomes. Neoplastic cells experience various oncogene-induced
forms of DNA damage and replication stress (including oxidative
DNA damage from reactive oxygen species (ROS) and
re-replication) throughout tumour progression. The ATR/CHK1
branch of the DDR may help pre-neoplastic cells endure
oncogenic stress, thereby promoting tumorigenesis21. Similarly,
the RAD18–TLS pathway is in essence a DNA-damage tolerance
mechanism that could help maintain viability in the face of
oncogene-induced replication stresses22. Therefore, RAD18–TLS
has the potential to have an impact on tumorigenesis by
promoting error-prone DNA synthesis and by conferring
oncogenic stress tolerance. However, whether dysregulation of
the TLS pathway has an impact on genome maintenance
mechanisms and phenotypes of cancer cells is unknown. Most
of our understanding of the mammalian RAD18–TLS signalling
pathway stems from studies performed in cultured cancer cell
lines. Remarkably, however, it is unknown whether RAD18 and
TLS are differentially regulated in cancer cell lines and
untransformed cells.
In this report we identify a cancer cell-specific protein, the
cancer/testes antigen (CTA) melanoma antigen-A4 (MAGE-A4),
as a novel binding partner and stabilizing factor for RAD18. CTA
proteins are ordinarily germ line restricted, yet can be aberrantly
expressed at high levels in many cancers23. The MAGE represent
a subclass of CTA24, some of which were recently shown to
associate with and activate specific RING E3 ubiquitin ligases25,
thereby providing a new mechanism by which ubiquitin
signalling is deregulated in cancer cells. Here we show that
MAGE-A4 contributes to TLS pathway activation, DNA-damage
tolerance and genome maintenance in cancer cells. These results
suggest a mechanism by which cancer genomes are impacted via
reprograming of ubiquitin signalling.
Results
MAGE-A4 is a component of the RAD18–RAD6 complex. To
identify new regulators of the TLS pathway we defined the
RAD18 protein interaction network in H1299 adenocarcinoma
cells using label-free affinity purification and shotgun mass
spectrometry (APMS). As a control we also investigated the
protein interaction network of a TLS-compromised RAD18
D402-444 mutant, which lacks a domain involved in mediating
binding to PolZ26,27 and other partners28 (Fig. 1a). RAD18
interaction networks were defined for HA–RAD18 wild
type (WT) and HA–RAD18 D402-444 complexes isolated from
undamaged cells and from genotoxin (ultraviolet or camptothecin
(CPT))-treated cultures.
Co-complexed proteins were separated from background
contaminants and false positives using the SAINT (significance
analysis of interactome) algorithm (Supplementary Data 1).
Top-scoring proteins included well-known RAD18 interactors
such as RAD6A and RAD6B (E2 ubiquitin-conjugating enzymes),
PCNA (a RAD18 substrate) and MSH2, a reported regulator
of RAD18 (ref. 29; Fig. 1b). As expected from previous work30,
PCNA binding to RAD18 D402-444 was decreased or
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undetectable (Fig. 1c and Supplementary Note 1). The complete
list of proteins detected in RAD18 complexes is available in
Supplementary Data 1. One of the highest confidence and
abundant novel RAD18 interactors we identified was the CTA
MAGE-A4 (Fig. 1c).
The presence of MAGE-A4 in the RAD18 complexes was
unaffected by ultraviolet or CPT, genotoxins that activate the
distinct TLS and DSB repair effector pathways of RAD18,
respectively. Comparison of relative MAGE-A4 abundance
between RAD18 WT and RAD18 D402-444 APMS revealed that
MAGE-A4 association does not depend on the PolZ-binding
domain of RAD18.
As the association of RAD18 with MAGE-A4 provided a
potentially important new relationship between DNA-damage
tolerance and cancer, we validated and further characterized the
RAD18–MAGE-A4 interaction. First, we confirmed the RAD18–
MAGE-A4 interaction in H1299 cells by performing independent
co-immunoprecipitation (co-IP) and immunoblotting experi-
ments (Fig. 1d).
A genome-wide screen previously detected MAGE-A4 as a
binding partner of the E3 ubiquitin ligase TRIM69 (ref. 31), a
mitotic regulator32. For the purpose of comparison with a known
MAGE-A4 partner, we expressed MYC epitope-tagged RAD18
and TRIM69 at similar levels in H1299 cells and examined levels
of MAGE-A4 associated with each E3 ligase by co-IP. In a side-
by-side comparison, RAD18 immune complexes contained more
MAGE-A4 than was present in TRIM69 immunoprecipitates
(Fig. 1e). Other E3 ubiquitin ligases we tested (HLTF1, SHPRH,
RNF8 and RNF168) failed to co-IP with MAGE-A4 (not shown).
We conclude that MAGE-A4 is a specific and constitutive
component of the RAD18 complex in H1299 lung carcinoma
cells.
MAGE-A4 associates with the RAD6-binding domain of RAD18.
E3 ubiquitin ligases share many common sequence motifs.
However, for the known MAGE-interacting RING-domain
E3 ligases, no single consensus sequence or domain of the
E3 is sufficient to mediate MAGE binding24,25. Therefore, we
performed experiments to map the MAGE-A4-interacting
domain of RAD18. We expressed the different functional
domains of the RAD18 protein as individual in-frame fusions
with glutathione S-transferase (GST) (Fig. 2a), then performed
‘pull-down’ assays to identify the MAGE-A4-binding domain(s)
of RAD18. As shown in Fig. 2b, the GST–RAD18 267-402
fragment, specifically recovered MAGE-A4 from H1299 cell
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Figure 1 | MAGE-A4 is a novel component of the RAD18 complex in cancer cells. (a) Domain organization of full-length RAD18 and RAD18 D402–444
(which harbours an internal deletion removing the PolZ-binding domain). (b) Spectral counts and estimated probability of true interaction by SAINT
analysis for selected proteins identified in HA–RAD18-WTand Control (HA) APMS experiments. (c) Total protein signal intensity versus relative abundance
between HA–RAD18-WT and HA–RAD18 D402–444 APMS. Signal intensity was normalized to the corresponding experiment’s bait intensity (x axis).
(d) H1299 cells were infected with adenoviruses encoding WT HA–RAD18, HA–RAD18 D402–444 or with an ‘empty’ control adenovirus. Infected cells
were treated with CPT (2mM) or UVC (20 Jm 2). Two hours (h) later, cell extracts were prepared and immunoprecipitated with anti-HA antibody-
conjugated magnetic beads. The resulting immune complexes and input fractions were analysed by immunoblotting with anti-HA and anti-MAGE-A4
antibodies. (e) Expression vectors encoding MYC–RAD18, MYC–TRIM69 or green fluorescent protein (GFP) (for control plasmid) were transiently
transfected into H1299 cells. Extracts from the resulting cells were immunoprecipitated with an anti-MYC antibody and the resulting immune complexes
(or input fractions) were analysed by immunoblotting with antibodies against MAGE-A4 and MYC.
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lysates. In reciprocal ‘pull-down’ experiments, GST–MAGE-A4
also recovered RAD18 from H1299 and 293T cell lysates
(Fig. 2c).
Interestingly, GST–RAD18 (267–402) contains the RAD6-
binding domain (amino acids 340–395) previously defined by
Watanabe et al.26. Similar to MAGE-A4, RAD6 was only
recovered from cell lysates with GST–RAD18 (267–402)
(Fig. 2b). To determine whether the RAD6-binding domain is
also involved in RAD18–MAGE-A4 complex formation in cells,
we determined the effect of internal deletion of amino acids
340–395 on the RAD18–MAGE-A4 association. Using transient
transfection, HA–RAD18 (WT) and HA–RAD18 D340–395
(Fig. 2d) were expressed at similar levels in H1299 cells
(Fig. 2e). However, in co-IP and immunoblotting experiments,
MAGE-A4 and RAD6 only associated with WT RAD18 (Fig. 2e).
We conclude that the RAD6-binding domain is necessary for
RAD18–MAGE-A4 interactions in vitro and in cells.
We considered the possibility that the association of
MAGE-A4 with RAD18 might be indirect and mediated via
RAD6. However, in pull-down experiments recombinant
GST–RAD6 did not recover MAGE-A4 from H1299 cell lysates
(Fig. 2f). To more carefully evaluate a role for RAD6 (or other
factors) in mediating the RAD18–MAGE-A4 interaction, we
performed binding studies using purified MAGE-A4 and
GST–RAD18 (267–402). As shown in Fig. 2g, we detected
specific association of RAD18 (267–402) with MAGE-A4 in the
absence of RAD6. Using ALPHAscreen-based protein proximity
assays33, we independently validated the association of
isolated MAGE-A4 (and of RAD6) with RAD18 (267–402)
(Supplementary Fig. 1). Interestingly, recombinant unlabelled
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Figure 2 | MAGE-A4 associates with the RAD6-binding domain of RAD18. (a) The indicated RAD18 fragments were expressed as GST fusions in E. coli.
The RAD6-binding domain spanning residues 267–402 is highlighted in red. (b) GST–RAD18 fragments were incubated with H1299 cell extracts. After
‘pull-down’ with GSH-sepharose beads, the recovered GST–RAD18 fusions and 5% of ‘input’ H1299 cell lysate were analysed by immunoblotting with
antibodies against GST, MAGE-A4 and RAD6. (c) GST–MAGE-A4 or GST was incubated with extracts from H1299 or 293T cells. After pulldown with
GSH-sepharose beads, the recovered GST proteins (and 5% of input cell extract) were analysed by immunoblotting with antibodies against GST and
RAD18. (d) Domain organization of full-length RAD18 and the RAD18 D340–395 (DR6BD) mutant harbouring an internal deletion that removes the
RAD6-binding domain. (e) H1299 cells were transiently transfected with expression plasmids encoding HA–RAD18 and HA–RAD18 D340–395 (DR6BD) or
with an empty vector control. Lysates from the resulting cells were immunoprecipitated with anti-HA antibodies. Anti-HA immune complexes and
inputs (20 mg) were analysed by immunoblotting with antibodies against RAD18, MAGE-A4 and RAD6. (f) Recombinant GST, GST–RAD18 267–402 or
GST–RAD6 were incubated with H1299 cell extracts then pulled down with GSH-sepharose beads. The recovered GST proteins were analysed by
immunoblotting with antibodies against MAGE-A4 and GST. (g) Recombinant GSTand GST–RAD18 267–402 were incubated with full-length recombinant
Hexa-histidine-tagged MAGE-A4 (His-MAGE-A4). GST proteins were recovered using GSH-sepharose beads. Recovered GST proteins (and 5% of input)
were analysed by immunoblotting with antibodies against GST and MAGE-A4.
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RAD6 competed with epitope-tagged MAGE-A4 for RAD18
binding both in vitro and in cells (Supplementary Fig. 1a–d).
However, gel filtration chromatography experiments show that
most of the cellular RAD6 is free and monomeric (Supplementary
Fig 1e–h). Moreover, from quantitative immunoblotting, RAD6
levels in H1299 cells exceed MAGE-A4 by 28-fold and exceed
RAD18 levels by 114-fold (Supplementary Fig. 2). Therefore,
MAGE-A4 is not sufficiently abundant in H1299 cells to
outcompete RAD6 for RAD18 association. We conclude that
MAGE-A4 is a specific binding partner of RAD18 and associates
with the RAD6-binding domain (as also reported for p95/NBS1)34.
MAGE-A4 promotes RAD18 stability. Reportedly, several
MAGE family members directly activate their partner E3 ligases
to promote substrate ubiquitination25. Therefore, we performed
in vitro ubiquitin ligase assays using recombinant proteins, to
determine the effect of MAGE-A4 on RAD18-directed PCNA
mono-ubiquitination. As shown in Fig. 3a, recombinant
MAGE-A4 did not stimulate RAD18-dependent PCNA
mono-ubiquitination under experimental conditions where
other MAGE proteins stimulate catalytic activities of their
cognate E3 ligases25. Interestingly, MAGE-A4 was ubiquitinated
by RAD18 (Fig. 3a). High molar ratios of MAGE-A4:RAD18 led
to decreased PCNA mono-ubiquitination in vitro (Fig. 3a). The
apparent mild inhibition of PCNA mono-ubiquitination by
MAGE-A4 in vitro results from substrate competition when
MAGE-A4 is in vast excess of PCNA (Fig. 3a, lanes 9–12).
The major substrate and distal effector of RAD18-mediated
ubiquitination in DNA damage tolerance is the sliding clamp
PCNA, which is present on replicating chromatin in the nucleus.
Although PCNA and RAD18 were present in both chromatin
and soluble fractions, MAGE-A4 was primarily soluble (Fig. 3b).
Moreover, in ultraviolet-irradiated H1299 cells, RAD18 but not
MAGE-A4 redistributed to nuclear foci representing sites of DNA
replication stalling (Fig. 3c and Supplementary Fig. 3). Taken
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Figure 3 | MAGE-A4 promotes RAD18 stability. (a) Recombinant RAD18–RAD6 complex (0, 0.27, 0.54 and 0.82 mM) was incubated with E1, ubiquitin
and purified PCNA. Reaction products were analysed by immunoblotting with antibodies against the indicated proteins. (b) Soluble and chromatin fractions
from H1299 cells were analysed by SDS–PAGE (20 mg per lane) and immunoblotting with antibodies against the indicated proteins. (c) H1299 cells were
transiently transfected with an expression plasmid encoding CFP-RAD18 (or empty vector for control), ultraviolet irradiated (20 Jm 2) and processed for
immunofluorescence microscopy after 6 h. Scale bar, 10mm. (d) H1299 and 293Tcells were transfected with two independent siRNAs targeting MAGE-A4
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together, the results of Fig. 3a–c suggest that MAGE-A4 may not
function as an allosteric activator of RAD18 or respond directly to
replication fork stalling. Accordingly, we investigated alternative
roles for MAGE-A4 in RAD18 regulation.
Proteins often stabilize their binding partners. Therefore, we
determined the effect of MAGE-A4 depletion on RAD18 levels.
As shown in Fig. 3d, we attained B90% depletion of MAGE-A4
in H1299 cells using two independent transiently transfected
small interfering RNAs (siRNAs). Interestingly, both MAGE-A4-
directed siRNAs led to substantial (92% and 73% decreases in
RAD18 expression in H1299 cells). Neither MAGE-A4-directed
siRNA affected RAD18 levels in 293T cells, which lack detectable
MAGE-A4 expression (Fig. 3d). Using cycloheximide treatment
to block new protein synthesis, we measured RAD18 decay
rates in control and MAGE-A4-depleted cultures. In control
(MAGE-A4 replete) H1299 cells, RAD18 was stable for at least
24 h (the duration of this experiment, see Fig. 3e). In MAGE-
A4-depleted cells, RAD18 expression was reduced and its half-life
decreased when compared with MAGE-A4-replete cells (Fig. 3e).
RAD18 depletion did not affect the half-life of MAGE-A4
(Fig. 3f). However, we note that MAGE-A4 levels exceed those of
RAD18 by B3-fold in H1299 cells (Supplementary Fig. 2).
Moreover, most of the cellular MAGE-A4 is not nuclear (Fig. 3c)
or in the same complex as RAD18 (Supplementary Fig. 1f–h),
explaining why RAD18 does not influence the overall MAGE-A4
pool.
Figure 3d–f suggested that MAGE-A4 stabilizes RAD18.
In previous work, proteasomal degradation of RAD18
(in USP7-depleted cells) was partially prevented by treatment
with the proteasome inhibitor MG132 (ref. 35). Therefore, we
determined the effect of MG132 treatments on RAD18 stability
in control (MAGE-A4 replete), MAGE-A4-depleted and
USP7-depleted H1299 cells. RAD18 levels were unaffected by
MG132 in MAGE-A4-replete H1299 cells in which RAD18 is
stable and has a half-life (t1/2) exceeding 24 h (Fig. 3e). However,
the reduced RAD18 stability in USP7- or MAGE-A4-depeleted
H1299 cells was partially rescued by MG132 treatment (Fig. 4a).
MG132-induced poly-ubiquitin laddering of RAD18 was also
decreased by ectopically expressed MAGE-A4 in 293T cells,
which lack endogenous MAGE-A4 (Supplementary Fig. 4). To
further test the effect of MAGE-A4 on RAD18 stability, we
reconstituted the ubiquitin-coupled proteolysis of RAD18 in a
cell-free rabbit reticulocyte lysate and compared the degradation
of immunopurified HA–RAD18 complexes from control and
MAGE-A4-expressing cells. As shown in Fig. 4b, HA–RAD18
derived from MAGE-A4 co-expressing 293T cells was degraded
less efficiently when compared with RAD18 from control cultures
lacking endogenous MAGE-A4. Taken together Figs 3a–f
and 4a,b show that MAGE-A4 protects RAD18 from ubiquitin-
coupled proteolysis.
The results of Fig. 2 suggest that MAGE-A4 increases RAD18
expression via direct binding. Therefore, we compared the stabi-
lizing effects of co-transfected MAGE-A4 on HA–RAD18 WT
and the MAGE-A4-interaction-deficient HA–RAD18 D340–395
mutant. As shown in Fig. 4c, levels of HA–RAD18 WT were
increased by co-expressed MAGE-A4. HA–RAD18 D402–444
(which is defective for PolZ interaction but binds MAGE-A4)
was also stabilized by co-expressed MAGE-A4. However, levels of
HA–RAD18 D340–395 (indicated by the white arrowhead in
Fig. 4c) were insensitive to MAGE-A4.
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stabilizes RAD18 via direct interactions with the RAD6-binding
motif and independently of RAD18 E3 ligase activity.
Next we asked whether stabilization of associated E3 ligases
represents a general mechanism for modulation of ubiquitin
signalling by MAGE-A4. We determined the effect of MAGE-A4
expression on TRIM69 levels. As shown in Fig. 4d, MAGE-A4
expression was inversely correlated with TRIM69 levels.
Therefore, the stabilizing effect of MAGE-A4 on RAD18
expression is relatively specific. Other MAGE-A4-associated E3
ligases have not been identified but eventually it will be
interesting to elucidate the basis for the differential effects of
MAGE-A4 on stability of its (putative) other E3 ligase partners.
Structural basis for MAGE-induced RAD18 stability. Previous
investigators have used deletion and truncation mutants to isolate
separable functional domains of MAGE proteins (albeit for
effectors other than RAD18)36,37. Therefore, we performed
structure–function analyses to define MAGE-A4 residues and
domains that are important for stabilizing RAD18. We generated
MAGE-A4 deletion mutants lacking or retaining the winged-helix
(WH)-A and WH-B regions of the MAGE-homology domain, as
illustrated in Fig. 5a. In addition, we generated a MAGE-A4
LL4AA mutant harbouring alanine substitutions in a di-Leucine
motif (L121 and L122) that is conserved between MAGE proteins
and is generally necessary for their interactions with E3 ubiquitin
ligase partners. We also generated a MAGE-A4 mutant with
an alanine substitution at Serine 90, a phosphorylated residue
present in RAD18-associated MAGE-A4 (Supplementary Data 1).
In transient transfections, the MAGE-A4 mutants were expressed
with different efficiencies in 293T cells. Most notably, mutants
lacking the WH-A and WH-B domains expressed poorly
when compared with full-length MAGE-A4 (Fig. 5b and
Supplementary Fig. 5). We compared the various MAGE-A4
mutants for RAD18-stabilizing activity. As expected, WT MAGE-
A4 extended the half-life of RAD18 fromB24 to450 h in 293T
cells (Fig. 5c,d). MAGE-A4 S90A retained RAD18-stabilizing
activity, indicating that MAGE-A4 S90 phosphorylation is
dispensable for regulating RAD18 expression levels (Supple-
mentary Fig. 5). MAGE-A4 LL4AA did not affect RAD18 levels,
suggesting that MAGE-A4–RAD18 interactions are necessary for
MAGE-A4 to stabilize RAD18.
All MAGE-A4 deletion mutants (including MAGE-A4 mutant
AB, which retains a pro-apoptotic carboxy-terminal domain of
MAGE-A4 previously shown to bind gankyrin36,37) failed to
stabilize RAD18. We conclude that the individual WH-A or
WH-B domains, or the entire MAGE-homology domain and its
flanking sequences alone are insufficient to confer RAD18
stability. Instead, it is most likely to be that multiple regions of
the MAGE-A4 protein act in a concerted non-separable manner
to stabilize RAD18.
The MAGE family members are highly conserved and may, in
some cases, have overlapping functions in activating their E3
ligase partners25. It was of interest to determine the extent to
which other MAGE family members stabilized RAD18. We were
able to ectopically express MAGE-A12, MAGE-B10 and MAGE-
A1 in 293T cells (Fig. 6a) and therefore these particular CTAs
were tested for RAD18-stabilizing activity. Unexpectedly, despite
the high conservation of primary sequences and domains between
different MAGE family members, only MAGE-A4 stabilized
RAD18 (Fig. 6b,c). Interestingly, these cycloheximide stability
experiments also showed that MAGE-A4 has a long half-life
(448 h) when compared with MAGE-B10, MAGE-A1 and
MAGE-A12. Therefore, MAGE-A4 is highly stable compared
with other MAGE family members and specifically stabilizes
RAD18.
MAGE-A4 promotes PCNA mono-ubiquitination and TLS.
Increased expression of RAD18 can substantially enhance both
basal and genotoxin-induced PCNA mono-ubiquitination5.
Therefore, we determined whether MAGE-A4 contributes to
RAD18-dependent TLS pathway activation in cancer cells. As
shown in Fig. 7a and Supplementary Fig. 6, siRNA-mediated
MAGE-A4 knockdown in H1299 cells led to an attenuation of
ultraviolet-inducible PCNA mono-ubiquitination. The reduced
PCNA ubiquitination of MAGE-depleted cells was rescued
by co-transfection of siRNA-resistant MAGE-A4 (Fig. 7a).
5-Bromodeoxyuridine (BrdU) labelling and fluorescence-
activated cell sorting analyses revealed no effect of MAGE-A4
depletion on DNA synthesis or cell cycle parameters (Fig. 7b).
Therefore, the reduced PCNA mono-ubiquitination of MAGE-
A4-depleted cells was not secondary to cell cycle changes.
As MAGE-A4 depletion led to reduced PCNA mono-
ubiquitination in H1299 cells, we also asked whether forced
expression of MAGE-A4 in cells lacking the protein endogen-
ously was sufficient to induce PCNA mono-ubiquitination. As
shown in Fig. 7c, ectopic overexpression of MAGE-A4 in A549
cells enhanced PCNA mono-ubiquitination in response to low
ultraviolet doses. Overexpressed MAGE-A4 did not affect PCNA
mono-ubiquitination in H1299 cells (which already express high
levels of endogenous MAGE-A4). MAGE-A4 also induced PCNA
mono-ubiquitination when ectopically expressed in non-trans-
formed mouse embryonic fibroblasts and human dermal
fibroblasts. MAGE-A4 expression did not induce PCNA mono-
ubiquitination in RAD18 / cells, demonstrating that the
stimulatory effect of MAGE-A4 on PCNA mono-ubiquitination
was RAD18 dependent.
As MAGE-A4 promotes RAD18-mediated PCNA mono-
ubiquitination (Fig. 7a–c), we determined the potential
contribution of MAGE-A4 to replication of damaged DNA.
RAD18-depleted cells fail to recover appropriately from DNA
damage-induced inhibition of DNA synthesis5. Interestingly,
MAGE-A4 depletion partially phenocopied the defective S-phase
recovery of RAD18-depleted H1299 cells from ultraviolet-
induced replication arrest (Fig. 7d). Moreover, co-depletion of
RAD18 and MAGE-A4 did not have additive inhibitory effects on
S-phase recovery after ultraviolet treatment (Fig. 7d). Similar to
phenotypes described in RAD18-depleted cells, the defective
recovery of MAGE-A4-depleted cells from S-phase arrest was
associated with persistence of gH2AX (Fig. 7e). RAD18
expression was also MAGE-A4 dependent in H157 and H650
adenocarcinoma cells and in U2OS osteosarcoma cells (which
express endogenous MAGE-A4; see Supplementary Fig. 7a,b).
Similar to H1299 cells, MAGE-A4 depletion led to an attenuation
of PCNA mono-ubiquitination and increased gH2AX after
ultraviolet treatment in U2OS cells (Supplementary Fig. 7c).
Taken together, the results of Fig. 7c–e indicate a role for MAGE-
A4 in facilitating TLS and recovery from DNA damage-induced
replication fork stalling.
To determine whether MAGE-A4 impacts RAD18-mediated
genome maintenance we used an established assay in which
RAD18 promotes error-free bypass of an ultraviolet-damaged
pSP189 reporter plasmid, thereby suppressing mutagenesis38.
As shown in Fig. 7f, ectopic expression of RAD18 in
293T cells suppressed mutagenesis of the ultraviolet-damaged
supF reporter by 40%, consistent with previous reports38.
Interestingly, MAGE-A4 expression alone led to a 31% decrease
in mutagenesis. When co-expressed with RAD18, MAGE-A4
further enhanced the suppressive effect of RAD18 on
mutagenesis. As expected, MAGE-A4 induced the expression
of endogenous and ectopically co-expressed RAD18 coincident
with suppression of mutagenesis (Fig. 7f). MAGE-A4
overexpression did not affect DNA synthesis rates or
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ultraviolet-checkpoint recovery of 293T cells (Supplementary
Fig. 8). Therefore, MAGE-A4 can specifically influence repli-
cative bypass of ultraviolet-induced DNA lesions, further
consistent with its novel role in regulating RAD18 levels and
TLS activity in cancer cells.
Discussion
Potts and colleagues25 made the seminal discovery that many
MAGE proteins bind and activate E3 ubiquitin ligases,
contributing to deregulated ubiquitin signalling in cancer cells.
Our work identifies RAD18 as a target of MAGE-A4 and provides
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a new potential mechanism by which genome maintenance and
genome stability can be altered in cancer cells.
There are interesting similarities and differences in the
relationship between MAGE-A4 and RAD18 when compared
with previously described MAGE-E3 ligase associations. For
example, the conserved di-leucine motif required by other
MAGE family members to activate their cognate E3 ligases25 is
also necessary for MAGE-A4 to stabilize RAD18. However,
although other MAGEs are allosteric activators of their
associated E3 ligases25, MAGE-A4 does not stimulate catalytic
activity of purified recombinant RAD18 under defined
in vitro conditions. Instead MAGE-A4 stabilizes RAD18 to
confer increased PCNA mono-ubiquitination and TLS.
Therefore, this study provides a new paradigm for MAGE-
induced reprograming of ubiquitin signalling via altered E3
ligase stability in cancer cells.
It is possible that MAGE-A4–RAD18 signalling also occurs
during normal mammalian development and in non-pathological
situations. Similar to MAGE proteins, Rad18 is expressed at high
levels in germ cells and male rad18 /mice have impaired
spermatogenesis and fertility39. However, in preliminary
experiments we have not detected Mage-a4 (or other Mage
proteins) in anti-RAD18 immunoprecipitates from mouse testes
extracts. Therefore, we favour the hypothesis that RAD18 binding
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is a ‘neomorphic’ activity of aberrantly expressed MAGE-A4 in
cancer cells.
Remarkably, although several MAGE-E3 ubiquitin ligase
complexes have been characterized25, no conserved sequence
motifs (on MAGE-A4 family member or E3 ligases) mediate these
protein–protein associations. Thus, the mechanism of association
appears to be different for every MAGE-E3 ligase complex. Our
structure–function analyses show that MAGE-A4 binds and
stabilizes RAD18 via the RAD6-binding domain. Reportedly,
p95/NBS1 also associates with the RAD6-binding domain of
RAD1834. Physiologically, RAD18 exists as an asymmetric
hetero-trimer comprising two RAD18 molecules in complex
with one molecule of RAD6 (ref. 40). Therefore, we hypothesize
that one RAD18 molecule in the [RAD18]2–RAD6 heterotrimer
has a ‘free’ RAD6-binding domain that is available to interface
with MAGE-A4, p95 and perhaps additional proteins. This
hypothesis predicts that MAGE-A4 and p95 (or other proteins)
may compete for RAD18 binding in cancer cells, and that such
competition may have an impact on genome maintenance
events involving RAD18–p95 associations. MAGE-A4 lacks the
RAD6-like b-sheet and therefore interacts with RAD18 via a
distinct mechanism. Clearly, biophysical and crystallographic
studies will be necessary to fully characterize the putative
[RAD18]2–RAD6–MAGE-A4 complex that exists in cancer cells.
The only other documented E3 ligase-binding partner of
MAGE-A4 is TRIM69 and the mechanism of MAGE-A4–
TRIM69 association has not been studied. Other known effectors
of MAGE-A4 are the transcription factor Miz1 (ref. 37) and the
liver oncoprotein gankyrin36, which both bind a C-terminal
region of MAGE-A4. We show here that the minimal MAGE-A4
C-terminal region (AB) that regulates Miz1 and gankyrin is
insufficient to stabilize RAD18. Indeed, none of the major
conserved MAGE-A4 domains retain RAD18-stabilizing activity
in isolation. Therefore, RAD18 binding is probably not a modular
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interaction mediated by individual MAGE-A4 domains. Instead,
the overall tertiary structure adopted by MAGE-A4 is likely to be
involved in the formation of the MAGE-A4–[RAD18]2–RAD6
complex. The finding that all MAGE-A4 mutants failed to
stabilize RAD18 may further support the idea that multiple
regions of the MAGE-A4 are required for its RAD18 association.
Other MAGE family members with a MAGE-A4-related domain
organization do not share RAD18-stabilizing activity, further
suggesting that unique or specific tertiary structural determinants
are required for MAGE-A4 to bind and stabilize RAD18.
Regardless of the mechanism of MAGE-A4–RAD18 interac-
tion, we show here that endogenous MAGE-A4 confers RAD18
stability and expression in cancer cells. TLS is generally assumed
to be a housekeeping genome maintenance mechanism and it has
not been suggested that expression or activities of core TLS
pathway components are significantly different between cell
types. However, expression levels of RAD18 and other TLS
proteins (including PolZ, Poli and PCNA) vary greatly between
different cultured cell lines (Supplementary Fig. 9). What then are
the possible consequences of variable RAD18 and TLS poly-
merase expression on genome stability and carcinogenesis?
RAD18-deficient cells do not recruit TLS polymerases to
replication forks5,15 and exhibit reduced lesion bypass activity17.
Conversely, RAD18 overexpression stimulates PCNA
ubiquitination, recruits Y-family polymerases to replication
forks, promoting TLS5,41. Therefore, the repertoire of
Y-family DNA polymerases and the degree to which different
TLS polymerases respond to RAD18 and PCNA mono-
ubiquitination may have enormous impact on genome stability
when RAD18 is present at aberrantly high levels. For example,
HeLa cells express unusually high levels of Poli compared with
H1299 cells (Supplementary Fig. 9). Poli has exceptionally low
fidelity, misincorporating dGTP more frequently than the correct
dATP across ‘T’ on undamaged templates42. Therefore, increased
RAD18 expression in a cell with aberrantly high Poli levels cell
will probably have a severe effect on replication fidelity. Polk
overexpression in cultured cells leads to insertions and
deletions43. Consequently, Polk activation in response to
aberrant RAD18 overexpression might cause elevated frequency
of indel mutations. Moreover, TLS polymerases have low
processivity compared with replicative DNA polymerases.
Therefore, elevated RAD18 expression and PCNA mono-
ubiquitination could lead to rampant recruitment of Y-family
polymerases to undamaged DNA, causing replication fork
slowdown and/or other defects that result in ‘fork collapse’ and
compromise genome stability due to DSB formation. A potential
role for MAGE-A4–RAD18 as a mutagenic driver or source of
genomic instability in cancer cells owing to inappropriate TLS
polymerase activation is highly likely.
Maiorano and colleagues41 recently showed that ectopic
RAD18 overexpression can lead to DNA damage tolerance.
Potentially, MAGE-A4-induced RAD18 expression might
contribute to tumorigenesis by enhancing DNA-damage
tolerance via TLS (and perhaps additional RAD18-mediated
DNA repair pathways such as homologous recombination44 and
cross-link repair28). Neoplastic cells must endure endogenous
stresses including ROS-induced DNA damage and other forms of
DNA replication stress45. Collectively, TLS polymerases can
perform bypass of oxidative lesions (such as 8-oxo-dG and AP
sites) potentially conferring tolerance of oncogene-induced ROS.
In addition, TLS polymerases can facilitate ongoing DNA
synthesis in cells undergoing oncogene-induced re-replication22
(one of the earliest responses to oncogene activation in
untransformed cells46). Therefore, increased TLS capacity
afforded by MAGE-A4–RAD18 may contribute to tolerance of
spontaneously arising DNA damage and replication stress,
thereby facilitating neoplastic cell survival and tumour
progression.
Clearly, future experiments are necessary to determine the
potential contribution of MAGE-A4 and RAD18 to genome
destabilization and tolerance of oncogenic stress. In addition to
promoting tolerance of intrinsic oncogene-induced sources of
stress (such as ROS and re-replication), RAD18 confers tolerance
of chemo/radiotherapy47,48. Therefore, the MAGE-A4–RAD18
signalling axis may represent an attractive druggable target whose
inhibition is innocuous to normal cells but selectively sensitizes
cancer cells to intrinsic and therapy-induced DNA damage and
replication stress.
Methods
Cell culture and transfection. hTERT-expressing human dermal fibroblasts were
provided by Dr William Kaufmann (UNC Chapel Hill). Primary mouse embryonic
fibroblasts were derived from E13.5 embryos of WT C57/BL6 mice. Cancer cell
lines H1299, A549, HeLa, U2OS, H157, H650, HCT116 and 293T were purchased
from the American Type Culture Collection (ATCC) and used for the described
experiments without further authentication. It is noteworthy that the H157
squamous cell lung carcinoma cell line is on the International Cell Line
Authentication Committee (ICLAC) misidentified cell list. According to the ATCC,
H157 is identical to the H1264 squamous cell lung carcinoma cell line. In the
experiments shown in Supplementary Fig. 7, H157 cells were used solely as one (of
several) example of independent cancer cell lines in which RAD18 expression is
MAGE-A4 dependent. All cell lines tested negative for mycoplasma contamination
using the ATCC Universal Mycoplasma Detection Kit (ATCC 301012K). All cell
lines were cultured in DMEM medium supplemented with 10% fetal bovine serum
and penicillin–streptomycin (1%). Plasmid DNA and siRNA oligonucleotides were
transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions, except that concentrations of plasmid DNA and Lipofectamine 2000
were used in each transfection reaction were decreased by 50% to reduce toxicity.
Adenovirus construction and infection. Adenovirus construction, purification
and infections were performed as described previously27,49. H1299 cells
were typically infected with 0.1 1.0 109 pfuml 1 and titrated to achieve
near-endogenous expression levels of RAD18 and other proteins.
Expression plasmids. GST-RAD18, GST-RAD6 and GST-MAGE-A4 were
expressed using the pGEX2T vector (GE Healthcare) and purified from BL21
(DE3) Escherichia coli (Invitrogen) as described previously27. Hexa-histidine-
tagged MAGE-A4 was expressed using the pRSET vector (Invitrogen V351-20) and
purified from BL21 (DE3) E. coli bacteria. Mammalian expression vectors for
HA- and MYC-tagged forms of RAD18 have been described previously26,27. To
generate MAGE-A4 expression vectors, the MAGE-A4 open reading frame was
PCR amplified from H1299 genomic DNA and subcloned into the pcDNA3.1( )
expression plasmid. MAGE-A4 mutants harbouring internal deletions and
individual nucleotide substitutions were derived by PCR using conventional
methods. The primers used to make MAGE-A4 mutants are: 50-F WT
(50-CGCGGATCCGCCACCATGTCTTCTGAGCAGAAGAGTCAGCAC-30),
30-R WT (50-AACAAGCTTTCAGACTCCCTCTTCCTCCTCTAACAAAG-30);
50-F HelixB (50-CGCGGATCCGCCACCATGGATGGCCTGCTGGGTAATAAT
CAG-30), 50-F HelixAþB (50-CGCGGATCCGCCACCATGTCCTTGTTCCGA
GAAGCACTCAGTAAC-30); DWHA-F (50-GCCTTTCCTATGGTCCAAG
GGC-30), DWHA-R (50-GCCCTTGGACCATAGGAAAGGC-30); DWHA-F
(50-TGACGCAGAGGATGGCCTGC-30), DWHA-R (50-GCAGGCCATCCT
CTGCGTCA-30); DWHB-F (50-GCCTTTCCTATGGTCCAAGGGC-30), DWHB-R
(50-GCCCTTGGACCATAGGAAAGGC-30); DMage-F (50-GACGCAGAGGGTC
CAAGGGC-30), DMage-R (50-GCCCTTGGACCCTCTGCGTC-30); L121/2A-F
(50-CTCATTTTGCGGCCCGCAAG-30), L121/2A-R (50-CTTGCGGGCCGCA
AAATGAG-30); S90A-F (50-GTTCCAGCGCCCAAGAAGAGG-30), S90A-R
(50-CCTCTTCTTGGGCGCTGGAAC-30); and S90D-F (50-GGGTTCCAGC
GATCAAGAAGAGG-30), S90D-R (50-CCTCTTCTTGATCGCTGGAACCC-30).
The identities of all complementary DNA inserts were confirmed by sequencing.
MYC–TRIM69 was a gift from Dr Angelique Whitehurst (UT Southwestern) and
expression plasmids encoding FLAG-tagged MAGE-A4, MAGE-A12, MAGE-B10
and MAGE-A1 were obtained from the UNC Tissue Culture Core Facility Orfeome
collection.
RNA interference. siRNAs were incubated with Lipofectamine 2000 and serum-
free Optimem for 15min at room temperature in the dark. Cells were then
trypsinized and resuspended in 1ml of medium and plated directly into the
siRNA/Optimem/Lipofectamine solution at 50% confluence and incubated for
72 h. Sequences of siRNA oligonucleotides used here are as follows: control
non-targeting siRNA, 50-UAGCGACUAAACACAUCAA-30 (Thermo Fisher
Scientific); RAD18 30-untranslated region siRNA, 50-UUAUAAAUGCCCAA
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GGAAAUU-30 ; MAGE-A4 siRNA #1, 50-AGUGUGAAUUCACCGUGAA-30 ,
MAGE-A4 siRNA #2 (targeting the 30-untranslated region), 50-GUGAAAUA
GGUGAGAUAAAUU-30 ; and USP7, 50-AAGCGUCCCUUUAGCAUUAUU-30.
For MAGE-A4 depletions, siRNA#1 was used unless otherwise indicated.
Genotoxin treatment. For ultraviolet C (UVC) treatment, growth medium was
removed from cultured cells and replaced with PBS. The resulting culture dishes
plates were irradiated using an ultraviolet cross-linker (Stratagene) or left untreated
for control. The UVC dose delivered to the cells was confirmed with an ultraviolet
radiometer (UVP, Inc.). Following ultraviolet or sham irradiation, cells were re-fed
with complete growth medium and returned to the incubator. For CPT treatments,
cells were treated with 2 mM CPT and incubated for 2 h.
Fluorescence microscopy. H1299 cells were grown toB60% confluency on glass-
bottom plates (Mat-tek) and then transfected with a CFP-RAD18-WT expression
plasmid. Twenty hours after transfection, cells were ultraviolet irradiated
(20 Jm 2) or sham treated and fixed 6 h later for staining with anti-MAGE-A4
and fixed-cell imaging on a Zeiss 710 confocal microscope, in the UNC Microscopy
Services Laboratory core facility, as described previously30.
Immunoprecipitation and immunoblotting. To prepare extracts containing
soluble and chromatin-associated proteins, monolayers of cultured cells typically in
60mm plates were washed three times in ice-cold PBS and lysed in 500 ml of ice-
cold cytoskeleton buffer (CSK buffer; 10mM Pipes pH 6.8, 100mM NaCl, 300mM
sucrose, 3mM MgCl2, 1mM EGTA, 1mM dithiothreitol, 0.1mM ATP, 1mM
Na3VO4, 10mM NaF and 0.1% Triton X-100) freshly supplemented with Protease
Inhibitor Cocktail and Phostop (Roche). Lysates were centrifuged at 1,000 g for
2min, to remove the CSK-insoluble nuclei. Supernatants were removed and further
centrifuged at 10,000 g for 10min, to obtain a clarified fraction containing a
mixture of cytosolic plus nucleosolic proteins. The detergent-insoluble nuclear
fractions were washed once with 1ml of CSK buffer and then resuspended in a
minimal volume of CSK before analysis by SDS–PAGE and immunoblotting.
For all immunoprecipitation experiments, input samples were normalized for
protein concentration. Magnetic beads containing covalently conjugated antibodies
against epitope tags were added to the extracts and incubations were performed
overnight at 4 C using rotating racks.
Immune complexes were recovered using magnetic stands. The beads were
washed five times with 1ml CSK (5–10min per wash), to remove nonspecifically
associated proteins. The washed immune complexes were boiled in protein loading
buffer for 10min, to release and denature for SDS–PAGE.
For immunoblotting, cell extracts or immunoprecipitates were separated by SDS-
PAGE, transferred to nitrocellulose membranes, and incubated overnight with the
following primary antibodies: PCNA (sc-56), Chk1 (sc-7898), b-actin (sc-130656),
cyclin E (sc-198), GAPDH (sc-32233), MAGE-A4 (sc-292429), Pan-MAGE-A
(sc71537) and GST (sc-53909) from Santa Cruz Biotech (Santa Cruz, CA); PolZ
(A301-231A), Poli (A301-304A), RAD6 (A300-281A), RAD18 (A301-340A) and
USP7 (A300-033A) from Bethyl Laboratories (Montgomery, TX); p42 MAPK (9107)
and MYC-Tag (2276) from Cell Signaling; gH2AX (05-636) from Millipore; and
Cdc45 rat monoclonal antibody as previously described50. Antibody dilutions used
for immunoblotting were 1:1,000, with exceptions for the following antibodies:
PCNA (1:500), GAPDH (1:2,000) and UH2AX (1:2,000). Uncropped images of the
most important western blottings are shown in Supplementary Fig. 10.
In vitro protein-binding assays with lysate. Mammalian cells were transfected
with 2 mg of plasmid and incubated for 48 h. Cell lysate was collected in CSK buffer
and centrifuged at 13,300 r.p.m. to clear lysate. Recombinant GST–RAD18 frag-
ments (100 ng) were incubated in 1ml CSK with 100 mg cleared lysate for 2 h at
4 C. Fifty microlitres of Glutathione sepharose beads (GE Healthcare 17-0756-01)
was added to the solution and incubated for 2 h more at 4 C. Beads and complexes
were collected by centrifugation and washed three times in CSKþ 1% BSA, then
resuspended in water and 4 Laemmli buffer and boiled for 10min.
In vitro RAD18–MAGE-A4 recombinant protein binding assay. Recombinant
6His–MAGE-A4 (1mg) was incubated in 1ml of CSKþ 1% BSA with either
GST or GST–RAD18 (0.3 mg) for 2 h at 4 C. Fifty microlitres of Glutathione
sepharose beads (GE Healthcare 17-0756-01) was added to the solution
and incubated for 2 h more at 4 C. Beads and complexes were collected by
centrifugation and washed three times in CSKþ 1% BSA, then resuspended in
water and 4 Laemmli buffer and boiled for 10min.
In vitro degradation of RAD18. HA–RAD18 was expressed alone or in combi-
nation with MAGE-A4 in 293T cells. Cells were collected using CSK buffer.
HA–RAD18 complexes were isolated by immunoprecipitation using anti-HA
magnetic beads (MBL Intl M-1329) for 2 h at 4 C. Beads were washed with CSK
and incubated for 1 h at 37 C in 2mM MgCl2, 1mM creatine phosphate,
25Uml 1 creatine phosphokinase (FisherSci, ICN10050990), PBS and
1mgml 1 of rabbit reticulocyte lysate, untreated (L4151), from Promega,
as a source of ubiquitination factors and proteasome activity, as described by
Hernandez-Pigeon et al.51.
Flow cytometry. Cells were labelled with 10mM BrdU immediately before harvest.
Cells were collected by trypsinization, fixed in 35% ethanol for 24 h, then stained
with anti-BrdU and propidium iodide as previously described27. Stained nuclei
were analysed by flow cytometry on an Accuri C6 flow cytometer (BD, Oxford,
UK) using the manufacturer’s software.
In vitro PCNA ubiquitination assay. Recombinant RAD18–RAD6 complex was
purified from baculovirus-infected Sf9 cells and incubated with recombinant
PCNA in the presence of E1, ubiquitin and an ATP-regenerating system as
described previously52.
SupF mutagenesis assay. 293T cells were co-transfected with a ultraviolet-irra-
diated (500 Jm 2) pSP189 reporter plasmid53 and control, RAD18 or MAGE-A4
expression vectors using Lipofectamine 2000. Forty-eight hours later, pSP189 was
recovered from the 293T cells using a DNA miniprep kit (Qiagen, Hilden,
Germany). Purified plasmid DNA was DpnI digested and electroporated into the
MBM7070 bacterial strain. The mutation frequency in the supF coding region was
determined by enumerating the ratios of blue (WT) and white (mutant) colonies.
Mass spectrometry. PBS-washed cell pellets from HA-RAD18-expressing
(and control) cells were lysed with CSK and digested with 1,000Uml 1 of RNase-
free DNase I (Roche) at 25 C for 30min. The resulting mixtures were sonicated to
dissociate the nuclei. Insoluble material was removed by centrifugation at 10,000 g
for 10min. The resulting supernatant (containing cytosol, nucleosol and solubilized
chromatin proteins) was used for immunoprecipitation of RAD18 complexes.
Anti-HA-conjugated magnetic beads (MBL Intl, M-1329) were incubated with
HA–RAD18-containing supernatant for 4 C for 3 h. Following incubation, beads
were washed in CSK. The protein complexes were digested directly off of the beads
using FASP Protein Digestion Kit (Protein Discovery #44250).
Peptides were separated by reversed-phase nano-high-performance liquid
chromatography with a nanoAquity UPLC system (Waters Corp.). Peptides were
first trapped in a 2-cm trapping column (75-mm inside diameter (ID), Michom
Magic C18 beads of 5.0-mm particle size, 200-Å pore size) and then separated on a
self-packed 25-cm column (75-mm ID, Michom Magic C18 beads of 5.0-mm
particle size, 100-Å pore size) at room temperature. The flow rate was
350 nlmin 1 over a gradient of 1% buffer B (0.1% formic acid in acetonitrile) to
30% buffer B in 200min. Next, a following wash raised buffer B to 70%. The
identity of the eluted peptides was determined with an in-line LTQ-Orbitrap
Velos mass spectrometer (Thermo Scientific). The ion source was operated
at 2.0–2.4 kV with the ion transfer tube temperature set at 250 C. Full MS scan
(300 to 2,000 m/z) was acquired in Orbitrap at 60,000 resolution setting; data-
dependent MS2 spectra were acquired in LTQ by collision-induced dissociation
with the 15 most intense ions. Precursor ions were selected on the basis of charge
states (2 or 3) and intensity thresholds (above 5,000) from the full scan; dynamic
exclusion (one repeat every 30 s, with a 60-s exclusion time window) was also taken
into account. The polysiloxane lock mass of 445.120030 was used throughout
spectral acquisition.
Protein identification, quantification and filtering. Raw data were analysed using
Sorcerer-SEQUEST (build 5.1.1, SageN Research) and the Transproteomic Pipeline
(TPP v4.7.1). MS/MS spectra were searched against the human UniProtKB/
Swiss-Prot sequence database (downloaded February 2015) supplemented with
common contaminants, that is, porcine (Swiss-Prot P00761) and bovine (P00760)
trypsin, and further concatenated with its reversed copy as a decoy. Search
parameters used were a precursor mass between 400 and 4,500 amu, up to 2 missed
cleavages, precursor-ion tolerance of 3 amu, accurate mass binning within
PeptideProphet, semi-tryptic digestion, a static carbamidomethyl cysteine
modification and variable methionine oxidation. False discovery rates were
determined by ProteinProphet and minimum protein probability cutoffs resulting
in a 1% false discovery rate were selected individually for each experiment. The
resulting spectral count data from controls and HA–RAD18-WT APMS
experiment were input into the Spotlite web application using SAINTexpress
(version 3.1.0), to determine protein–protein interaction probabilities by modelling
the expected spectral count distribution of true and false interactions. In addition,
raw data were re-searched and signal intensity was quantified using the MaxQuant
LFQ algorithm with the identical sequence database and search parameters, except
a 20-p.p.m. precursor mass tolerance, fully tryptic digestion and match between
runs were used.
Data availability. The authors declare that the data supporting the findings of this
study are available within the article and its Supplementary Information files.
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